We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Public Health Risk of Designer Psychotropic Drugs: Should PHASE Be Phased In?
- Authors
Greenblatt, David J.
- Abstract
Investigators at the US Food and Drug Administration (FDA) have proposed an I in silico i process, termed Public Health Assessment via Structural Evaluation (PHASE), to assist in the early identification of potentially harmful designer drugs. The PHASE proposal uses as a prototype the comparison of fentanyl to a number of fentanyl analogues.[9] Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs.
- Subjects
DESIGNER drugs; PSYCHIATRIC drugs; FENTANYL; PUBLIC health; SYNTHETIC marijuana; ENDORPHIN receptors
- Publication
Clinical Pharmacology & Therapeutics, 2019, Vol 106, Issue 6, p1175
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1002/cpt.1578